Two medicine stores under scanner for ‘illegal' sale of abortion kits in Cuttack
CUTTACK: Two medicine stores were on Tuesday allegedly found selling abortion kits illegally, in gross violation of the Medical Termination of Pregnancy (MTP) Act-1971.
Acting on a tip-off, officials of the Directorate of Drug Control raided around three medicine shops - two in Ranihat and one in Arunoday market. The raids were conducted by assistant drug controllers of Circle-I and Circle-II Dharmadev Puhan and Tushar Ranjan Panigrahi respectively.
During the searches, the officials recovered several abortion kits (Mifepristone and Misoprostol combination pack) from two medicine stores, one each in Ranihat and Arunoday localities.
'Though the purchase source of the combined composition packed MTP kits were found to be authentic, the owners of the two medicine stores failed to show the requisite documents that could suggest they were selling the kits with due prescription. We will submit the raid report to the Directorate of Drug Control for issuance of show cause notice and for order on suspension of licence of these two shops in respect of purchase and sale,' said Puhan.
The combined composition packed MTP kits should be used within a certain period of gestation at authorised healthcare facilities with the prescription of a gynaecologist as it involves in serious health risk including heavy bleeding and other complications. But, the MTP kits are being sold and used without prescription leading to a rise in maternity mortality, Puhan added.
'Earlier, we had created awareness and now have started carrying out enforcement to curb the illegal sale and use of MTP kits,' he said adding, special focus is on the medicine shops operating near colleges and other educational institutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
Regulating Hope: India's ART Act, Global Best Practices, and the Drive for Research Excellence
Assisted Reproductive Technology ( ART ) has transformed fertility care, bringing renewed hope to countless individuals and couples facing infertility. In response to the growing demand and complexity of ART services, India introduced the Assisted Reproductive Technology (Regulation) Act, 2021—an important step toward creating a safe, ethical, and accountable environment for reproductive treatments. By setting clear standards and oversight mechanisms, the Act lays a strong foundation for responsible practice. As the field continues to evolve, there is an opportunity to build on this progress by enabling a supportive ecosystem for research, innovation, and collaboration—ensuring that India remains responsive to emerging technologies while upholding the rights and well-being of all stakeholders. The ART Act: India's Regulatory Milestone The Assisted Reproductive Technology (Regulation) Act, 2021 was introduced to regulate and supervise ART clinics and banks across India, aiming to prevent misuse and ensure that all procedures are carried out in a safe and ethical manner. To achieve this, the Act established a comprehensive, multi-tiered regulatory framework comprising the National and State ART and Surrogacy Boards , a National Registry, and designated authorities at both the central and state levels. These bodies are responsible for overseeing the registration, functioning, and monitoring of ART clinics and banks, enforcing prescribed standards, and maintaining a central database to support transparency and informed policy-making. Among the Act's key provisions are the mandatory registration of all ART clinics and banks, the requirement for written informed consent from all parties involved, and strict protocols for record-keeping and reporting. Additionally, the Act regulates the sourcing, storage, and handling of gametes, explicitly prohibits sex selection and the commercial sale of gametes or embryos, and includes safeguards to protect the rights and welfare of children born through ART procedures. Together, these measures address a wide range of ethical, medical, and legal concerns, while fostering responsible advancements in the field of reproductive medicine. Global Perspectives United States The US model relies on a combination of federal oversight (primarily through the Centers for Disease Control and Prevention and the Food and Drug Administration) and state-level regulation. Accreditation by professional bodies such as the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) ensures high standards of practice and transparent outcome reporting. However, there is significant variability in access and donor anonymity laws across states. Spain Spain is recognized for its progressive, patient-centric approach. The country's national law guarantees broad access to ART, including for single women and same-sex couples. Donor anonymity is strictly enforced, and a comprehensive national registry tracks all procedures and outcomes. Spain's robust oversight has made it a global destination for fertility care. China China's ART sector is tightly regulated by the government, with access limited to married couples. Clinics and banks operate under strict licensing, and there are clear restrictions on embryo storage and use. The centralized approach ensures uniform standards but limits individual choice. Japan Japan's regulatory environment is evolving, with guidelines issued by professional societies and increasing government involvement. Donor anonymity is maintained, and there is a cautious approach to expanding ART services, reflecting societal consensus and ethical considerations. India's take on Research and Innovation India's approach to research and innovation in assisted reproductive technology (ART), including emerging fields like genetic testing and embryo research is evolving. India's in vitro fertilization (IVF) industry is undergoing a significant transformation, driven by rising infertility rates, technological advancements, and increased awareness of fertility treatments. Guidelines and Regulation of ART-Related Research and ICMR India has established regulatory frameworks for ART through the Assisted Reproductive Technology (ART) Act, 2021, and the Surrogacy (Regulation) Act, 2021, which set out ethical and safety standards for ART practices. The ART Act includes strict guidelines on embryo use, prohibiting embryos from being used for purposes other than ART or research, and bans the transfer of gametes/embryos outside India for research or as a source of stem cells. Embryo donation for research is allowed only in specific cases and with written consent. Genetic testing and pre-implantation genetic testing (PGT) are mandated in certain cases to screen embryos for genetic diseases or when medically indicated, reflecting a cautious but proactive approach to integrating new technologies. However, research involving human germline gene therapy, reproductive cloning, and clinical trials with xenogeneic cells is not permitted. In vitro genome modification of embryos (not carried to term) is allowed, but only up to 14 days of fertilization. As of 2025, India does not have specific laws regulating human embryo gene editing. Instead, oversight is provided through guidelines issued by the Indian Council of Medical Research (ICMR). According to the National Guidelines for Stem Cell Research, genome editing—including methods like CRISPR-Cas9—on stem cells, germ-line cells, gametes, or embryos is allowed only for in vitro studies. Such research must be reviewed by the IC-SCR, IEC, and IBSC, and approved by the RCGM. Clinical application of germline gene editing is currently strictly prohibited. Need to Incentivize Research and Innovation There is broad recognition among policymakers and experts of the need to incentivize research and innovation in the medical field, especially in fertility and ART. The government has launched the National Policy on Research and Development and Innovation in Pharma-MedTech Sector and the PRIP (Promotion of Research and Innovation in Pharma MedTech Sector ) scheme, which aims to: Create a regulatory environment that facilitates innovation and research in product private and public investment in innovation through fiscal and non-fiscal industry-academia collaboration and support research in priority areas, including stem cell therapy and complex generics. Nitiz Murdia – Managing Director Indira IVF says, 'Experts and stakeholders in the fertility sector highlight the need for greater awareness, expanded access, insurance coverage, and government-backed initiatives to address India's fertility challenges and to support the growth of ART services and research'. References: This article is written by Nitiz Murdia, Managing Director at Indira IVF (DISCLAIMER: The views expressed are solely of the author and does not necessarily subscribe to it. shall not be responsible for any damage caused to any person/organisation directly or indirectly)
Deccan Herald
11 hours ago
- Deccan Herald
Transgenders continue to face discrimination in Pakistan despite 2018 law promising equality
Seven years after the Pakistan census officially recognised transgender people and six years after The Transgender Persons (Protection of Rights) Act, 2018, came into effect, the biggest problem the community faces is a lack of hygienic living spaces.
Indian Express
13 hours ago
- Indian Express
Haryana records decline in sale of pregnancy termination kits: officials
The sale of Medical Termination of Pregnancy (MTP) has declined sharply over the past three months from 40,763 in the first fortnight of March to just 470 kits between May 27 and June 9, according to Haryana Food and Drugs Administration (FDA) Department data. Officials attribute the success to the ongoing crackdown by the State Task Force (STF) on illegal abortions in the state, battling a skewed sex ratio. Concerned over the state's declining sex ratio — 910 girls per 1,000 boys at birth in 2024, the lowest in eight years — authorities have intensified crackdown on the illegal sale of MTP kits and monitoring transaction of kits from authorised wholesalers. Haryana has 32 authorised wholesalers selling MTP kits to registered MTP centres. According to data, between March 1 and 15, Haryana recorded the sale of 40,763 MTP kits, with a staggering 39,000 kits sold in Sonipat district alone. The trend continued in the first fortnight of April, recording the sale of 25,721 kits, but drastically declined in the second fortnight, with only 1,492 kits sold. The sale of MTP kits dropped further to just 470 between May 27 and June 9. State Drug Controller Manmohan Taneja told The Indian Express, 'Wholesalers have been strictly instructed to sell MTP kits only to authorised MTP centres on the recommendation of a registered medical practitioner. We have mandated record-keeping for every tablet, and any violations will be dealt with strictly.' During an STF meeting, chaired by Haryana Additional Chief Secretary for Health Sudhir Rajpal on Tuesday, officials reported: 'Twenty-nine wholesalers recorded zero sale of MTP kits between June 3 and 9.' In April, Rajpal directed authorities to compile lists of wholesalers of MTP kits, along with records of their stocks, to ensure the sales are restricted only to registered MTP centres. He also ordered inspections of centres conducting MTP procedures on pregnant women who have two girl children, and warned centres found guilty of conducting female feticide would face closure. Rajpal stressed the urgent need for action on show-cause notices issued to MTP centres, urging immediate cancellation of licenses of gynaecologists found complicit in sex-selective abortions. Officials said terminating a pregnancy could be done surgically or with M TP kits, but self-administering these medications without medical supervision posed severe health risks. Taneja previously explained that an MTP kit consists of five tablets—one mifepristone and four misoprostol — both classified as Schedule-H drugs, meaning a valid prescription from an RMP is required for the purchase of a kit that comes with a warning: 'To be used only under the direct supervision of a gynaecologist.' Officials believe the impact of the ongoing initiatives will start delivering results by August-September, leading to an improvement in the sex ratio at birth. From June 3 to 9 this year, the child sex ratio at birth was recorded at 943 girls per 1,000 boys. During the STF meeting on May 20, the sex ratio for the preceding week was noted at 922, while on April 10, it stood at 911 girls per 1,000 boys. However, officials involved in the campaign emphasised these figures reflect temporary fluctuations and suggested waiting a few more months to assess a meaningful and sustained change in the sex ratio at birth.
